REG - Oxford Biomedica PLC - Oxford Biomedica Notes Homology Q2 Report

Oxford BioMedicaAnnouncement

16/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220816:nRSP1472Wa&default-theme=true

RNS Number : 1472W  Oxford Biomedica PLC  16 August 2022

 

 

Oxford Biomedica notes Homology Medicines' quarterly report and confirms
financials for Oxford Biomedica Solutions LLC are in line with expectations

Oxford, UK - 16 August 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a leading gene and cell therapy group, notes the
release of Homology Medicines' ("Homology") quarterly report for the three
months ended 30 June 2022. Financial information on Oxford Biomedica Solutions
LLC ("Oxford Biomedica Solutions") contained within Homology's 10-Q is in line
with Company expectations. To view Homology's announcement see: Form 10-Q
(https://investors.homologymedicines.com/node/8901/html) .

Oxford Biomedica Solutions, 20% owned by Homology, is a US-based full scope,
AAV manufacturing and innovation business offering a unique 'Plug & Play'
platform and fully integrated end-to-end capabilities, including from vector
design and process development through to clinical trials.

Oxford Biomedica Solutions has a robust business pipeline and maintains its
financial guidance. The Company is committed and confident about securing two
new Adeno-Associated Virus (AAV) customer partnerships by the end of calendar
year 2022.

-Ends-

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Neal / Matthew Cole

 

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform,
which the Group leverages to develop product candidates in-house, before
seeking partners to take the products into clinical trials.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica
Solutions, a new US based subsidiary AAV manufacturing and innovation
business, based near Boston, US.

 

Oxford Biomedica employs more than 940 people. Further information is
available at www.oxb.com (http://www.oxb.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUNOVRUKUWARR